Page 232 - Genentech News Today

– A federal judge threw out a lawsuit against the maker of an anti-malarial drug blamed for causing psychotic behavior and neurological damage to U.S.

Third quarter revenue increased 31% year over year to $94.2 million Third quarter GAAP operating loss of $32.5 million, non-GAAP operating income of $3.0 million ... | December 1, 2022

The review comes after a student news outlet detailed suspected problems with Marc Tessier-Lavignes research papers.

DUBLIN--(BUSINESS WIRE)--The "Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.The 'Novel Anti...

The review comes after a student news outlet detailed suspected problems with Marc Tessier-Lavignes research papers.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

The drug, lecanemab also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.

The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out. U.S. District Court Judge Trina Thompson ruled

Actinogen Medical is a biotech with a potentially "gazillion" dollar opportunity in its Alzheimer's drug